medigraphic.com
ISSN 0326-3428 (Print)
Órgano de difusión científica de la Asociación Nefrológica de Buenos Aires

2021, Number 4

<< Back Next >>

Rev Nefrol Dial Traspl 2021; 41 (4)

Progression to chronic kidney disease according to albuminuria in diabetic nephropathy patients with preserved renal function

Ri KH, Na KR, In LJ, Lee E, Rok HY, Eun CD, Wook LK, Wan JJ

Language: English
References: 27
Page: 249-256
PDF size: 177.48 Kb.


ABSTRACT

Background: Albuminuria predicts progression of diabetic nephropathy (DN) but lacks specificity and sensitivity for the diagnosis of chronic kidney disease (CKD) and progressive decline in estimated glomerular filtration rate (eGFR). We evaluated the decline in renal function in patients with DN and analyzed the prognosis of renal function according to the level of albuminuria and the incidence of cardiovascular disease (CVD), cerebrovascular diseases, and peripheral artery disease (PAD) according to the level of albuminuria. Methods: This retrospective study included 331 patients with eGFR ›60 mL/min/1.73 m2 and urinary albumin/creatinine (Cr) ratio (ACR) ›30 mg/g Cr who were treated at the Chungnam National University Hospital between January 2012 and December 2018. Patients were divided into mildly increased albuminuria, moderately increased albuminuria, and severely increased albuminuria groups according to their urine ACRs of 30-300, 300- 900, and ›900 mg/g Cr, respectively. Renal outcomes and incidence of CVD, cerebrovascular disease, and PAD were compared among the three groups. Results: More severe albuminuria was associated with higher rates of progression to CKD (P ‹ 0.001) and ›50% reduction in eGFR from baseline (P ‹ 0.001). There was a statistically significant difference in the rate of PCI with angina or myocardial infarction (P=0.030). However, cerebrovascular disease and PAD did not significantly differ among the three groups. Conclusion: Among patients with DN who maintained a relatively preserved renal function with an eGFR ›60 mL/min/1.73 m2, the rates of renal deterioration and progression to CKD were significantly more frequent in those with more severe albuminuria.


REFERENCES

  1. Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de BoerIH, Goldstein-Fuchs J, et al. Diabetic kidney disease: areport from an ADA Consensus Conference. DiabetesCare. 2014;37(10):2864-83. doi: 10.2337/dc14-1296.

  2. Wang Y, Zhou T, Zhang Q, Fei Y, Li Z, Li S, et al. Poorrenal and cardiovascular outcomes in patients withbiopsy-proven diabetic nephropathy. Kidney Blood PressRes. 2020;45(3):378-90. doi: 10.1159/000505919.

  3. Thomas MC, Cooper ME, Zimmet P. Changingepidemiology of type 2 diabetes mellitus and associatedchronic kidney disease. Nat Rev Nephrol. 2016;12(2):73-81. doi: 10.1038/nrneph.2015.173.

  4. González Suárez ML, Thomas DB, Barisoni L, FornoniA. Diabetic nephropathy: Is it time yet for routinekidney biopsy? World J Diabetes. 2013;4(6):245-55. doi:10.4239/wjd.v4.i6.245.

  5. Standards of Medical Care in Diabetes-2017: Summaryof Revisions. Diabetes Care. 2017;40(Suppl 1):S4-S5.doi: 10.2337/dc17-S003.

  6. Aboelnasr MS, Shaltout AK, AlSheikh MR, AbdelhameedAH, Elrefaey W. Diabetic kidney disease in patientsnewly diagnosed with type-2 diabetes mellitus:incidence and associations. Saudi J Kidney Dis Transpl.2020;31(1):191-9. doi: 10.4103/1319-2442.279940.

  7. Selby NM, Taal MW. An updated overview of diabeticnephropathy: Diagnosis, prognosis, treatment goals andlatest guidelines. Diabetes Obes Metab. 2020;22(Suppl1):3-15. doi: 10.1111/dom.14007.

  8. Norris KC, Smoyer KE, Rolland C, Van der VaartJ, Grubb EB. Albuminuria, serum creatinine, andestimated glomerular filtration rate as predictors ofcardio-renal outcomes in patients with type 2 diabetesmellitus and kidney disease: a systematic literaturereview. BMC Nephrol. 2018;19(1):36. doi: 10.1186/s12882-018-0821-9.

  9. Macisaac RJ, Ekinci EI, Jerums G. Markers of and riskfactors for the development and progression of diabetickidney disease. Am J Kidney Dis. 2014;63(2 Suppl2):S39-62. doi: 10.1053/j.ajkd.2013.10.048.

  10. Hojs R, Ekart R, Bevc S, Hojs N. Biomarkers of renaldisease and progression in patients with diabetes. J ClinMed. 2015;4(5):1010-24. doi: 10.3390/jcm4051010.

  11. Doshi SM, Friedman AN. Diagnosis and managementof type 2 diabetic kidney disease. Clin J Am Soc Nephrol.2017;12(8):1366-73. doi: 10.2215/CJN.11111016.

  12. Afkarian M, Zelnick LR, Hall YN, Heagerty PJ,Tuttle K, Weiss NS, et al. Clinical manifestations ofkidney disease among US adults with diabetes, 1988-2014. JAMA. 2016;316(6):602-10. doi: 10.1001/jama.2016.10924.

  13. UK Prospective Diabetes Study Group. Tightblood pressure control and risk of macrovascularand microvascular complications in type 2 diabetes:UKPDS 38. BMJ. 1998;317(7160):703-13.

  14. Afkarian M, Sachs MC, Kestenbaum B, HirschIB, Tuttle KR, Himmelfarb J, et al. Kidney diseaseand increased mortality risk in type 2 diabetes. JAm Soc Nephrol. 2013;24(2):302-8. doi: 10.1681/ASN.2012070718.

  15. Perkovic V, Agarwal R, Fioretto P, Hemmelgarn BR,Levin A, Thomas MC, et al.; Conference Participants.Management of patients with diabetes and CKD:conclusions from a “Kidney Disease: Improving GlobalOutcomes” (KDIGO) Controversies Conference.Kidney Int. 2016;90(6):1175-83. doi: 10.1016/j.kint.2016.09.010.

  16. Colhoun HM, Marcovecchio ML. Biomarkers ofdiabetic kidney disease. Diabetologia. 2018;61(5):996-1011. doi: 10.1007/s00125-018-4567-5.

  17. Berhane AM, Weil EJ, Knowler WC, Nelson RG,Hanson RL. Albuminuria and estimated glomerularfiltration rate as predictors of diabetic end-stagerenal disease and death. Clin J Am Soc Nephrol.2011;6(10):2444-51. doi: 10.2215/CJN.00580111.

  18. Yokoyama H, Araki S, Haneda M, Matsushima M,Kawai K, Hirao K, et al.; Japan Diabetes Clinical DataManagement Study Group. Chronic kidney diseasecategories and renal-cardiovascular outcomes in type2 diabetes without prevalent cardiovascular disease: aprospective cohort study (JDDM25). Diabetologia.2012;55(7):1911-8. doi: 10.1007/s00125-012-2536-y.

  19. Solomon SD, Lin J, Solomon CG, Jablonski KA,Rice MM, Steffes M, et al.; Prevention of Eventswith ACE Inhibition (PEACE) Investigators.Influence of albuminuria on cardiovascular riskin patients with stable coronary artery disease.Circulation. 2007;116(23):2687-93. doi: 10.1161/CIRCULATIONAHA.107.723270.

  20. Vupputuri S, Nichols GA, Lau H, Joski P, Thorp ML.Risk of progression of nephropathy in a populationbasedsample with type 2 diabetes. Diabetes ResClin Pract. 2011;91(2):246-52. doi: 10.1016/j.diabres.2010.11.022.

  21. Packham DK, Alves TP, Dwyer JP, Atkins R, deZeeuw D, Cooper M, et al. Relative incidence ofESRD versus cardiovascular mortality in proteinurictype 2 diabetes and nephropathy: results from theDIAMETRIC (Diabetes Mellitus Treatment for RenalInsufficiency Consortium) database. Am J Kidney Dis.2012;59(1):75-83. doi: 10.1053/j.ajkd.2011.09.017.

  22. Zhou J, Chen X, Xie Y, Li J, Yamanaka N, Tong X. Adifferential diagnostic model of diabetic nephropathyand non-diabetic renal diseases. Nephrol Dial Transplant.2008;23(6):1940-5. doi: 10.1093/ndt/gfm897.

  23. Olsen S, Mogensen CE. How often is NIDDMcomplicated with non-diabetic renal disease? Ananalysis of renal biopsies and the literature. Diabetologia.1996;39(12):1638-45. doi: 10.1007/s001250050628.

  24. Nzerue CM, Hewan-Lowe K, Harvey P, MohammedD, Furlong B, Oster R. Prevalence of non-diabetic renaldisease among African-American patients with type IIdiabetes mellitus. Scand J Urol Nephrol. 2000;34(5):331-5. doi: 10.1080/003655900750048378.

  25. Prakash J, Sen D, Usha, Kumar NS. Non-diabeticrenal disease in patients with type 2 diabetes mellitus. JAssoc Physicians India. 2001;49:415-20.

  26. Williams DM, Nawaz A, Evans M. Renal outcomesin type 2 diabetes: a review of cardiovascular and renaloutcome trials. Diabetes Ther. 2020;11(2):369-86. doi:10.1007/s13300-019-00747-3.

  27. Skov J, Christiansen JS, Poulsen PL. Hypertensionand diabetic nephropathy. Endocr Dev. 2016;31:97-107. doi: 10.1159/000439393.




2020     |     www.medigraphic.com